A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/045 (2006.01) A61K 31/122 (2006.01) A61K 31/555 (2006.01) A61P 31/14 (2006.01) A61P 31/18 (2006.01)
Patent
CA 2556437
A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide ("DMSO"); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with viruses such as Hepatitis C and HIV-1.
L'invention concerne une formulation pharmaceutique et son utilisation. Ladite formulation pharmaceutique contient une espèce peroxydique ou des produits de réaction résultant de l'oxydation d'un alcène, tel qu'un géraniol, par un agent d'oxydation contenant de l'oxygène, tel que l'ozone; un solvant de pénétration, tel qu'un diméthylsulfoxyde (DMSO); un colorant contenant un métal chélaté, tel qu'une hématoporphyrine; et un composé redox aromatique, tel qu'une benzoquinone. On utilise cette formulation pharmaceutique pour traiter efficacement des patients affectés par des virus tels que le virus de l'hépatite C et du VIH-1.
Hofmann Robert F.
Kirby Eades Gale Baker
Torquin Llc
LandOfFree
Use of targeted oxidative therapeutic formulation in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of targeted oxidative therapeutic formulation in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of targeted oxidative therapeutic formulation in... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1524262